The purpose of this study is to develop an early diagnostic method for familial amyloidotic polyneuropathy (FAP) 
Introduction
Family trees carrying FAP have been reported from various countries including Portugal, Israel, Finland, Germany, Sweden, Brazil, U. S. A., and Japan (1) . Type I FAP (FAP')' of Japanese origin is characterized by dissociated sensory disturbance and autonomic dysfunction in the early course, followed by motor amyloid protein of familial amyloidotic polyneuropathy that contains a methionine-for-valine substitution at position 30 of transthyretin; TFA, trifluoroacetic acid; TTR, transthyretin. neuropathy (2) . The illness is always progressive to death either from cardiac or renal failure associated with the systemic deposition of amyloid fibrils.
The diagnosis of advanced cases depends on characteristic clinical manifestations together with demonstration of amyloid deposition at biopsy. However, there has been no definite diagnositic method for this progressive disorder before symptoms appear. The mean age of onset is 34 ± 5 (SD) yr and patients tend to have one or two children before they develop clinical manifestations of the disease. Since this disorder is transmitted by autosomal dominant inheritance and the clinical onset is postmarital, it is important to develop an early diagnostic method to predict possible transmission of the disease. A (9) .
Amino acid analyses. Amino acid analysis was performed on a model 835 automated amino acid analyzer (Hitachi, Ltd., Tokyo, Japan). The peptides and proteins were hydrolyzed in 6 N HO containing 0.1% phenol and 0.02% 2-mercaptoethanol at 1 10°C for 24 h.
Statistics. Statistical analysis was performed by an independent t test ( Table I ). P value of <0.05 was considered significant. The results were expressed as a mean±SD.
Results RIA for FAP nonapeptide. The antiserum raised against FAP nonapeptide could bind 35-40% of 125I-labeled FAP nonapeptide at a final dilution of 50,000. A standard curve of the RIA is illustrated in Fig. 1 . The sensitivity (effective dose, 10%) of the RIA for FAP nonapeptide was 21 pg/tube, and 238 pg of the peptide were required to reduce binding by 50% (effective dose). Intraassay and interassay coefficients of variation were 7.5 and 6.8%, respectively (n = 10). were 17.6, 18.1, and 18.8 ng. These results corresponded to 296, 305, and 318 ng of the variant TTR, respectively; therefore, the recovery rate was 61% as a mean. The RIA recovery was checked in every assay to validate the quantitative precision. The recovery rate was almost constant in every assay, ranging from 58 to 65%.
Serum levels of the variant and total TTR. also possible that identical paternal and maternal TTR genes are expressed simultaneously in normal individuals. cDNA for human TTR has been recently cloned and its nucleotide sequence has been determined (19) . One allele of TTR gene in FAP' patients has undergone mutation resulting in guanine-toadenine transition in the 5' terminal position ofthe valine codon at position 30. This transition is responsible for the substitution of methionine for valine. FAP' is considered to be transmitted by this abberant TTR gene. Measurement of the serum variant TTR can serve as a new, noninvasive diagnostic method for the disease. It is also helpful as a wide screening test for the population of districts inhabited by conglomerations of diseased families. We can also predict whether or not a member of an FAP' family who is younger than the age of usual onset is likely to develop the disease in the future. Furthermore, members of families with FAP' can do better family planning, being assured whether or not they can have children without worrying about transmission of the disorder. This RIA is applicable for the detection of the variant TTR in the tissue samples as well as in the serum. It would be a quick method for identifying amyloid fibril protein of the various types of FAP in the world, for which a method has not yet been determined. SAFTmMet-30 is present in FAP' patients from Portugal, Sweden, Japan, and other countries, which indicates that this RIA can be widely applied to FAP' throughout the world for early diagnosis and genetic counseling before the childbearing age.
